Innate Pharma Announces Conference Simply call and Webcast for 2021 Initial Quarter Company Update

Marseille, France, May perhaps 04, 2021 (Globe NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421 Nasdaq: IPHA) (“Innate” or the “Corporation”), now declared that the Business will hold a convention get in touch with on Thursday, Could 11, 2021 at 3 p.m. CEST / 9 a.m. ET, to give an update on small business progress for the duration of the initially quarter of 2021.

Participating in the call will be Innate Pharma’s Chief Government Officer Mondher Mahjoubi, MD, Main Health care Officer Joyson Karakunnel, MD, MSc, FACP, and Main Monetary Officer Frédéric Lombard, MBA.

Facts for the Digital Party

The stay webcast will be readily available at the adhering to link:

Individuals may also be part of via telephone to inquire inquiries by registering in progress of the event at Upon registration, members will be supplied with dial-in numbers, a direct party passcode and a one of a kind registrant ID that they may use 10 minutes prior to the occasion commence to accessibility the call. Call reminders will also be sent to registered members via e-mail the day prior to the function.

This facts can also be uncovered on the Buyers area of the Innate Pharma web site, A replay of the webcast will be accessible on the Enterprise internet site for 90 times pursuing the function.

About Innate Pharma:

Innate Pharma S.A. is a global, medical-phase oncology-centered biotech company dedicated to bettering cure and scientific outcomes for people as a result of therapeutic antibodies that harness the immune method to fight cancer.

Innate Pharma’s broad pipeline of antibodies contains various potentially very first-in-course scientific and preclinical candidates in cancers with substantial unmet health-related need.

Innate has been a pioneer in the knowledge of normal killer cell biology and has expanded its experience in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This revolutionary tactic has resulted in a diversified proprietary portfolio and significant alliances with leaders in the biopharmaceutical marketplace which include Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France, with a US business in Rockville, MD, Innate Pharma is detailed on Euronext Paris and Nasdaq in the US.

Find out far more about Innate Pharma at

Information and facts about Innate Pharma shares:

ISIN code

Ticker code



Euronext: IPH Nasdaq: IPHA



This press launch contains selected forward-wanting statements, like people inside the meaning of the Personal Securities Litigation Reform Act of 1995. The use of particular words, such as “believe,” “potential,” “expect” and “will” and equivalent expressions, is supposed to identify forward-looking statements. While the company thinks its anticipations are centered on affordable assumptions, these forward-on the lookout statements are subject matter to several risks and uncertainties, which could trigger true success to differ materially from those people anticipated. These dangers and uncertainties include things like, among other factors, the uncertainties inherent in investigation and enhancement, which include linked to security, progression of and outcomes from its ongoing and prepared scientific trials and preclinical scientific tests, critique and approvals by regulatory authorities of its products candidates, the Company’s commercialization initiatives, the Company’s ongoing potential to elevate capital to fund its improvement and the in general effects of the COVID-19 outbreak on the global healthcare system as properly as the Company’s business enterprise, financial issue and final results of functions. For an more dialogue of pitfalls and uncertainties which could result in the company’s genuine effects, economic problem, effectiveness or achievements to differ from people contained in the ahead-wanting statements, be sure to refer to the Danger Factors (“Facteurs de Risque”) section of the Common Registration Document filed with the French Economical Marketplaces Authority (“AMF”), which is offered on the AMF web site or on Innate Pharma’s website, and general public filings and studies filed with the U.S. Securities and Trade Fee (“SEC”), including the Company’s Yearly Report on Kind 20-F for the year ended December 31, 2020, and subsequent filings and reviews filed with the AMF or SEC, or or else manufactured general public, by the Firm.

This push launch and the details contained herein do not constitute an give to offer or a solicitation of an offer you to purchase or subscribe to shares in Innate Pharma in any region.

For extra data, please get in touch with: